SLNO — Soleno Therapeutics Share News
0.000.00%
Last trade - 00:00- $2.76bn
- $2.56bn
- $190.41m
Soleno jumps as analysts say US nod for rare disease drug transforms treatment options
U.S. STOCKS ON THE MOVE-Tesla, Alphabet, GameStop
Soleno gains as US FDA approves its drug to treat rare genetic disorder
U.S. RESEARCH ROUNDUP- Advanced Micro Devices, Carmax, Lockheed Martin
US FDA greenlights first-ever treatment for rare genetic disorder (updated)
US FDA greenlights first ever treatment for rare metabolic disorder
Brief: Soleno Therapeutics Inc - FDA Approves Soleno's Vykat XR For Hyperphagia In Prader-Willi Syndrome - SEC Filing
Stifel resumes Soleno coverage with 'buy' rating, citing potential of rare disease drug
Soleno Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Soleno Therapeutics Enters Into $200 Million Debt Financing With Oxford Finance Llc
Soleno falls after FDA rejects peer Applied's genetic disease drug
U.S. STOCKS ON THE MOVE-Goldman Sachs, Zoom, Rumble
U.S. STOCKS ON THE MOVE-Pinterest, Best Buy, Chevron
Soleno Therapeutics falls as FDA extends review of genetic disorder drug
Brief: Soleno Therapeutics Announces FDA Extension Of Review Period For DCCR
Soleno Therapeutics Inc reports results for the quarter ended in January 1 - Earnings Summary
Brief: Soleno Therapeutics Announces The Passing Of Former Chairman Ernest Mario
Brief: The Carlyle Group Inc Reports 6.2% Stake In Soleno Therapeutics As Of Oct 10 Versus 8.1% As Of Oct 8 - SEC Filing
Brief: Carlyle Group Reports 8.1% Stake In Soleno Therapeutics As Of Oct 8 Versus 9.9% As Of Sept 6- SEC Filing